Special Authority approvals for abiraterone; subsidised units and patients dispensed abiraterone, goserelin, flutamide, and bicalutamide in 2018/19, 2019/20 and 2020/21

Date sent: 17 May 2022

OIA response

Thank you for your request dated 14 April 2022 under the Official Information Act 1982 (OIA) for information relating to prostate cancer medicines.

You requested we provide information to you per the excel template included in your request.

Please find attached a copy of the excel template with data populated per the tables provided.

We trust that this information answers your queries. We are making our information more freely available, so we now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.

2022 OIA request data Special Authority approvals for abiraterone subsidised units and patients dispensed abiraterone goserelin flutamide and bicalutamide [XLSX 16 KB]